NASDAQ: ITRM
Iterum Therapeutics PLC Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their ITRM stock forecasts and price targets.

Forecast return on equity

Is ITRM forecast to generate an efficient return?

Company
-169.48%
Industry
153.19%
Market
81.87%
ITRM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ITRM forecast to generate an efficient return on assets?

Company
15.51%
Industry
36.07%
ITRM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ITRM earnings per share forecast

What is ITRM's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.86
Avg 2 year Forecast
-$0.57
Avg 3 year Forecast
-$0.31

ITRM revenue forecast

What is ITRM's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$930.0k
Avg 2 year Forecast
$3.7M
Avg 3 year Forecast
$30.5M

ITRM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ITRM$1.03N/AN/A
ATRA$6.14$21.00+242.02%Strong Buy
RVPH$0.75$8.25+1,005.90%Strong Buy
RNXT$0.95$6.00+531.58%Buy
OKUR$2.73$32.25+1,081.32%Strong Buy

Iterum Therapeutics Stock Forecast FAQ

What is ITRM's earnings growth forecast for 2025-2027?

(NASDAQ: ITRM) Iterum Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Iterum Therapeutics's earnings in 2025 is -$24,774,000.On average, 1 Wall Street analyst forecast ITRM's earnings for 2025 to be -$29,740,008, with the lowest ITRM earnings forecast at -$29,740,008, and the highest ITRM earnings forecast at -$29,740,008. On average, 1 Wall Street analyst forecast ITRM's earnings for 2026 to be -$19,711,401, with the lowest ITRM earnings forecast at -$19,711,401, and the highest ITRM earnings forecast at -$19,711,401.

In 2027, ITRM is forecast to generate -$10,720,236 in earnings, with the lowest earnings forecast at -$10,720,236 and the highest earnings forecast at -$10,720,236.

If you're new to stock investing, here's how to buy Iterum Therapeutics stock.

What is ITRM's revenue growth forecast for 2025-2028?

(NASDAQ: ITRM) Iterum Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.

Iterum Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ITRM's revenue for 2025 to be $32,160,707, with the lowest ITRM revenue forecast at $32,160,707, and the highest ITRM revenue forecast at $32,160,707. On average, 1 Wall Street analysts forecast ITRM's revenue for 2026 to be $127,605,384, with the lowest ITRM revenue forecast at $127,605,384, and the highest ITRM revenue forecast at $127,605,384.

In 2028, ITRM is forecast to generate $1,053,003,782 in revenue, with the lowest revenue forecast at $1,053,003,782 and the highest revenue forecast at $1,053,003,782.

What is ITRM's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ITRM) forecast ROA is 15.51%, which is lower than the forecast US Biotechnology industry average of 36.07%.

What is ITRM's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ITRM) Iterum Therapeutics's current Earnings Per Share (EPS) is -$1.26. On average, analysts forecast that ITRM's EPS will be -$0.86 for 2025, with the lowest EPS forecast at -$0.86, and the highest EPS forecast at -$0.86. On average, analysts forecast that ITRM's EPS will be -$0.57 for 2026, with the lowest EPS forecast at -$0.57, and the highest EPS forecast at -$0.57. In 2027, ITRM's EPS is forecast to hit -$0.31 (min: -$0.31, max: -$0.31).

What is ITRM's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ITRM) forecast ROE is -169.48%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.